✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Zydus Lifesciences Ltd.

ZYDUSLIFE

Market Cap
₹89,530 Cr.
P/E
19.78

Zydus Lifesciences Ltd.

  • Zydus Lifesciences
  • Lupin
  • Dr. Reddy's Lab
  • TJI Pharma
FAQs on Zydus Lifesciences Ltd. Shareprice

Zydus Lifesciences has given lower returns compared to its competitors.
Zydus Lifesciences has grown at ~32.56% over the last 2yrs while peers have grown at a median rate of 37.94%

Zydus Lifesciences is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Zydus Lifesciences is 19.63, while 3 year average PE is 21.83.
Also latest EV/EBITDA of Zydus Lifesciences is 18.22 while 3yr average is 15.73.

View FAQ's On Business
Growth Table
  • Zydus Lifesciences Ltd.
  • Lupin
  • Dr. Reddy's Lab
Balance Sheet
  • Zydus Lifesciences Ltd.
  • Lupin
  • Dr. Reddy's Lab
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Zydus Lifesciences Ltd.
  • Lupin
  • Dr. Reddy's Lab
Cash Flow
  • Zydus Lifesciences Ltd.
  • Lupin
  • Dr. Reddy's Lab
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Zydus Lifesciences Ltd.
  • Lupin
  • Dr. Reddy's Lab
Quarterly Results
  • Zydus Lifesciences Ltd.
  • Lupin
  • Dr. Reddy's Lab
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Zydus Lifesciences Ltd. Financials

Balance sheet of Zydus Lifesciences is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Zydus Lifesciences is increasing.
Latest net debt of Zydus Lifesciences is ₹213 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹1,441.1 Crs.

Yes, profit is increasing.
The profit of Zydus Lifesciences is ₹4,615 Crs for TTM, ₹3,860 Crs for Mar 2024 and ₹1,960 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Zydus Lifesciences latest dividend payout ratio is 7.82% and 3yr average dividend payout ratio is 14.83%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech